HOME >> BIOLOGY >> NEWS
Finding the right recipe: Researchers tailor magnetic nanoparticles for medical treatment & diagnosis

Nanoparticles that possess magnetic properties offer exciting new opportunities for delivering drugs to targeted areas in the body, replacing radioactive tracer materials, improving the quality of noninvasive medical imaging, and producing ever-smaller data storage devices. But before these magnetic nanoparticles gain widespread use, scientists must learn to consistently control their key properties.

Using only variations in chemistry and process conditions, researchers at the Georgia Institute of Technology have learned to precisely control the size and magnetic properties of one class of magnetic nanoparticles. Their goal is a "recipe book" other researchers could use to produce nanoparticles with exactly the right properties for different applications.

"If you are going to produce these nanoparticles for large-scale use, you cannot guess at the conditions or rely on intuition," said Dr. John Zhang, Georgia Tech assistant professor of chemistry and biochemistry. "We are understanding the fundamental ways to control the properties of these particles, chemically manipulating the magnetic interactions at the atomic level. We want to control these properties through chemical means."

Zhang will present his research team's latest findings at the 219th national meeting of the American Chemical Society March 26, 2000 in San Francisco. The team includes Adam J. Rondinone, Anna C.S. Samia, Chao Liu, and Richard Anderson.

Because each potential application for the magnetic nanoparticles requires different properties, the work is essential to their future use as carriers of drugs, tracers and MRI contrast enhancement agents. Also, it will provide insights to some key technical issues in high density information storage.

For instance, each particle possesses certain magnetic orientations just as the north or sout
'"/>

Contact: John Toon
john.toon@edi.gatech.edu
404-894-6986
Georgia Institute of Technology Research News
26-Mar-2000


Page: 1 2 3 4

Related biology news :

1. Findings suggest need for new view of p53 cancer proteins interaction with DNA
2. Finding the hole in the defenses of cavity-creating microbes
3. Findings redefine mechanism of action of RNA helicase enzymes
4. Findings of novel nanoproperties in selenium produced by bacteria open new area of exploration
5. Finding may help eczema sufferers tolerate smallpox vaccine
6. Findings could aid efforts to harness nature for making drugs
7. Findings offer clue to how molecule can both stimulate, suppress cell growth
8. Findings offer further understanding about growth and development in young male gymnasts
9. Findings in frog oocytes may help study of chromosome physiology
10. Finding dirty bombs and other radiation threats
11. Finding life away from Earth will be tough task, says noted paleontologist

Post Your Comments:
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ... announced today the acquisition of Turner Medical, Inc ., thus becoming a ... to the Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s ...
(Date:7/1/2015)... 2015   Decision Resources Group finds ... Otezla are its oral administration, alternative mechanism of ... surveyed rheumatologists. Otezla was the first oral therapy ... active psoriatic arthritis in the United ... includes conventional oral treatments including disease-modifying antirheumatic drugs ...
(Date:7/1/2015)... 1, 2015   Neuraltus Pharmaceuticals, Inc. , a ... groundbreaking drugs to treat neurodegenerative diseases such as ... Robert G. Miller , M.D., Director of the Forbes ... Pacific Medical Center in San Francisco, has been awarded ... million to help fund a Phase 2 clinical ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... A newly ... new ideas to lower the barriers to innovation in life sciences R&D. The Pistoia ... to two cash prizes of US$15,000 and a period of expert mentorship from a ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
Cached News: